jump to navigation

Allegro Diagnostics Enters License Agreement with Boston University 07/08/2011

Posted by Morse Barnes-Brown Pendleton in Client News.
Tags: , ,
trackback

On June 29th, MBBP client Allegro Diagnostics, Inc. announced that it has entered into an exclusive license agreement with MBBP client Boston University and the University of Utah Foundation for intellectual property related to Allegro Diagnostics’ molecular testing platform which utilizes a genomic biomarker to detect early signs of lung cancer. Mike Webb, President and CEO of Allegro Diagnostics, describes the agreement:

Allegro Diagnostics is committed to bringing early lung cancer detection to the standard of care. The licensing agreement with Boston University and the University of Utah Foundation helps us to achieve that goal by supporting our continued advancement of this breakthrough platform, including the planned commercial launch of BronchoGen™ in the first half of 2012.

For more information please read the full press release.

Comments»

No comments yet — be the first.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: